AbbVie (XTER:4AB) Short Interest


XTER:4AB AbbVie Inc XTER:4AB
81 GF Score
Price €213.00
GF Value €182.32
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XTER:4AB vs MRK, JNJ, AMGN: Short Interest Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbbVie Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Short Interest distribution charts can be found below:

* The bar in red indicates where AbbVie's Short Interest falls into.


XTER:4AB
81GF Score
AbbVie Inc XTER:4AB
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AbbVie (XTER:4AB) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of €213.00 is trading 16.8% above its estimated GF Value™ of €182.32. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for XTER:4AB:

  • Short Interest:
  • GF Value™: €182.32 vs. price of €213.00 (16.8% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the XTER:4AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
81GF Score

Get the complete analysis for XTER:4AB

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€213.00
Price
€182.32
GF Value